Advanced Imaging Reveals Genomic 'Achilles' Heel' in Cancer Cells, Enhancing Treatment Vulnerability

A new study led by NYU Langone Health and its Perlmutter Cancer Center has identified a small subset of vulnerable DNA sites that make cancer cells highly sensitive to targeted drugs called PARP inhibitors. This discovery, published in Nature Cell Biology, reveals how the location of DNA damage can influence treatment response and provides a foundation for developing new biomarkers for cancer drug sensitivity.